Series “Reading 2025 Layoffs”: Modality-by-Modality: Manufacturing, Regulatory, and Commercial Realities (Part 3)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 3 Key Takeaways The “capital-efficiency equation” is modality-specific: even with similar P2 wins, cell/gene/RNA/antibody–degrader programs require very different...
